Participated · Series A · Feb 2026

Flextock is an Egypt-founded startup building what it calls an “operating system” for e-commerce across Egypt and Saudi Arabia. Its single platform lets online merchants manage warehousing, fulfilment, last-mile delivery aggregation, cross-border shipping, multi-channel sales access and working-capital financing. By unifying these typically fragmented services, the company aims to eliminate service gaps, improve visibility and boost operational efficiency for small and mid-sized merchants. The embedded finance module leverages logistics data to underwrite and collect repayments, turning fulfilment volumes into a credit-distribution advantage. Management believes the modular suite can increase revenue per customer as merchants adopt additional features over time. Proceeds from the latest round will fund expansion of operational infrastructure, enhancement of the end-to-end product suite and accelerated merchant acquisition in its core markets. No public operating metrics such as revenue or user counts were disclosed in the article.

Participated · Series B · Jan 2024

On February 24, 2021, 依生生物制药有限公司 announced completion of a Series B financing of more than $130 million. The round was co‑led by Oceanpine Capital (海松资本) and OrbiMed (奥博资本). Following the transaction, the company's institutional investor base included Oceanpine, OrbiMed, 斯道资本, F‑Prime Capital, 3W Capital, 高瓴资本, Adjuvant Capital, 和玉资本, AIHC, 益普资本, Superstring Capital and 海通国际. 易凯资本 served as the company's exclusive financial adviser on the deal. The financing expanded the company's investor roster and represents a significant recapitalization event at the B‑round stage. No additional product, operational or use‑of‑proceeds details for the company were provided in the articles.

Led · Equity · Aug 2023

Founded in 2018 by Peking University alumni Zhang Linfeng and Sun Weijie, DP Technology develops a suite of artificial-intelligence tools aimed at speeding up scientific discovery across multiple disciplines. Its flagship offerings include Particle Universe for molecular simulations, Uni-Lab for laboratory operations, Bohrium as a cloud research hub and Hermite for computer-aided drug design. Additional products such as RiDYMO (targeting “undruggable” biology), Piloteye (battery design), SciMaster (a general scientific AI agent) and Lebesgue Intelligent Computing (network traffic control) broaden its reach. The company’s technology is reportedly used by more than 1,000 universities and research organizations and 150 corporate clients, including PetroChina and BYD Auto. Co-founder Zhang Linfeng, an ACM Gordon Bell Prize winner, positions the firm’s mission as building “AI scientists” that can automate discovery. With its newly secured Series C funding, DP Technology plans to expand hiring and accelerate R&D on additional AI-driven scientific tools. The startup has now raised $114 million to support these ambitions.

Participated · Seed · Jul 2023

Kaso provides a B2B platform that digitizes and automates procurement between restaurants and food suppliers to improve efficiency, transparency and reduce food waste. The core product digitizes the relationship between restaurants and suppliers and targets the food supply chain. Kaso currently operates in KSA and the UAE and serves over 5,000 partners in those markets. The company intends to use new funding to expand operations and enhance its technology platform. Management has set a target to achieve a GMV of $1 billion within 12 months. Kaso was founded by Manar Alkassar and Ahmed Soliman.

Participated · Series B · Aug 2022

Sironax is a Beijing-based clinical-stage biotechnology company dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Its pipeline comprises multiple programs focused on key mechanisms including regulated cell death, neuroprotective pathways and neuroinflammation, with lead efforts around RIPK1 inhibitors. The company is conducting early clinical studies with SIR0365 and SIR2446 while advancing additional preclinical research. Sironax plans to use recent financing to support ongoing clinical development of its RIPK1 portfolio and to expand its R&D footprint and pipeline of potential best- and first-in-class candidates. The company closed a $200M Series B led by Gaorong Capital and Yunfeng Capital, with participation from a broad group of existing and new investors. Led by CEO Aaron Ren and founded in 2017, Sironax is positioning to progress its clinical programs targeting age-related degeneration.